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CNS tumors are the most common solid 
tumors of childhood [1]. Although treat-
ment advances have improved survival 
for some pediatric CNS diseases, there 
unfortunately remains a group of tumors 
associated with significantly poorer prog-
nosis. Among these are high-grade gliomas 
(HGG), which, despite aggressive manage-
ment, usually recur and are associated with 
5-year survival outcomes between 15–35% 
[2]. Diffuse intrinsic pontine glioma 
(DIPG), a highly malignant brainstem 
tumor with median survival of less than 
1 year [3], remains a constant therapeutic 
challenge. High-risk metastatic medullo-
blastoma with cerebrospinal fluid dissem-
ination at presentation is associated with 
5-year survival rates between 40–70% 
despite intensive treatment regimens [4]. In 
addition, rare malignancies, such as atypi-
cal teratoid rhabdoid tumors, although 
often demonstrating response to chemo-
therapy, are associated with early relapse 
and a median survival of only 17 months 
[5]. Oncolytic virotherapy, which uses 
viruses to selectively infect and destroy 
cancer cells [6], offers a novel treatment 
approach for poor prognosis pediatric 
CNS tumors. While there is extensive lit-
erature on oncolytic virotherapy for adult 
brain malignancies, such as HGG, work 
on pediatric CNS tumors is currently only 
just gathering steam. With no open clini-
cal trials focused on oncolytic virotherapy 
in pediatric CNS tumors we can currently 
only draw upon available preclinical mod-
els, alongside adult and limited pediatric 
clinical data, to progress the exciting future 
potential of this treatment modality. 
The majority of preclinical studies of 
oncolytic virotherapy for pediatric CNS 
tumors evaluate efficacy in medulloblas-
toma. Over 15 years ago Lasner et al. pub-
lished that herpes simplex virus (HSV) 
variant 1716 could infect and destroy 
D283 medulloblastoma cells and dem-
onstrated that intratumoral injection 
of the virus into D283 tumor-bearing 
mice conferred a statistically signif i-
cant increase in survival compared with 
control murine models [7]. Pyles et al. 
1 year later also demonstrated therapeu-
tic potential in a double mutated modi-
fied HSV strain 3616UB that was able to 
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literature on oncolytic virotherapy 
for adult brain malignancies…
work on pediatric CNS tumors 
is currently only just gathering 
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replicate in, spread through and arrest growth 
of DAOY cell xenografts in CD17 severe com-
bined immunodeficiency mice [8]. In 2003, 
Yang et al. established the potential of human 
reovirus type 3 for oncolytic virotherapy in 
medulloblastoma. The authors demonstrated 
susceptibility of medulloblastoma cells to reo-
virus in five out of seven medulloblastoma cell 
lines, as well as in primary cultures derived 
from surgical specimens and in two cell lines 
obtained from spontaneously arising tumors in 
Patched-1+/- mice [9]. Furthermore, a significant 
survival advantage was shown following single 
and multiple intratumoral injection of reovirus 
into DAOY cell orthotopic mouse models over 
controls, with multiple administrations also 
reducing spinal and leptomeningeal metasta-
ses [9]. More recently, Studebaker et al. have 
also demonstrated the potential for oncolytic 
virotherapy in treatment of disseminated dis-
ease. The authors showed that medulloblastoma 
cells were susceptible to killing with recombi-
nant measles virus [10]. They then went on to 
generate and characterize a mouse model of 
disseminated disease that, when treated with 
intraventricular measles virus, significantly 
increased survival of animals when compared 
with controls treated with inactivated virus [11]. 
Other publications have demonstrated that 
medulloblastoma is sensitive to myxoma [12] 
and seneca valley virus (SVV) infection [13]. 
Interestingly, Yu et al. showed that a single tail 
vein injection of SVV-001 in immunodeficient 
orthotopic xenograft mouse models of medul-
loblastoma resulted in widespread infection 
of the xenografts, demonstrating that virus 
penetration through the blood–brain barrier is 
possible [13]. This is extremely promising in the 
context of the clinical applicability of oncolytic 
virotherapy and the potential for intravenous 
systemic delivery. 
Unlike its adult counterpart, only a small 
amount of research has focused on oncolytic 
virotherapy for pediatric HGG, although pub-
lished work has evaluated a role for HSV and 
SVV. Freidman et al. have shown that a pedi-
atric cerebellar glioblastoma xenograft DM456 
contains tumor and cancer stem cells that are 
more sensitive to killing by a range of modified 
HSVs than adult glioma xenografts [14]. One 
such HSV IL-12 producing virus (M002), which 
demonstrated killing in DM456, is thought to 
be particularly promising as a potential clini-
cal therapeutic agent [15]. This is a result of its 
demonstrated safety in primate toxicity studies 
and its superior anti-tumor activity in murine 
models over HSV G207 [16], which has previ-
ously been used in adult glioblastoma clinical 
trials [17]. An adult clinical trial is in develop-
ment and, if safe, it is hoped that this may prog-
ress to a pediatric trial [15]. SVV (NTX-010) was 
tested on a range of pediatric tumors including 
the brain tumors glioblastoma, medulloblastoma 
and ependymoma [18]. Although the most consis-
tent cytotoxic effects were seen in neuroblastoma 
and rhabdomyosarcoma lines, some objective 
response was also seen in the glioma lines: NTX-
010 was not effective on the medulloblastoma 
and ependymoma lines in this study [18]. Further 
preclinical studies evaluating the efficacy and 
safety of existing and emerging oncolytic viruses 
in pediatric HGG are required. In addition, the 
role of oncolytic viruses for malignancies such 
as atypical teratoid rhabdoid tumors and DIPG 
remains to be explored. 
Although clinical testing of oncolytic virother-
apy for pediatric CNS tumors is in its infancy, 
there are already a handful of encouraging reports 
in the literature that lay the foundations for 
future clinical work. Csatary et al. report three 
pediatric patients (18 months to 12 years at diag-
nosis) with malignant grade III/IV glioma who, 
following the failure of conventional treatment, 
went on to receive regular intravenous therapy 
with the Newcastle disease virus MTH-68/H 
for several years. At time of publication, all three 
patients still continued with maintenance virus 
therapy and demonstrated between 7–9 years 
survival with good quality of life [19]. Further-
more, a case report describes a 12-year-old boy 
with chemotherapy- and radiotherapy-resistant 
grade III anaplastic astrocytoma, who received 
intravenous and inhaled MTH-68/H along-
side valproic acid. This led to dramatic regres-
sion of his original tumor; however, it did not 
repress the growth of two further tumors, which 
ultimately led to his death [20]. Encouragingly, 
Newcastle disease virus antigen and constituents 
were found in tumor tissue confirming success-
ful systemic delivery of the virus to the tumor 
and demonstrating the virus’s ability to infect 
and replicate in pediatric human cancer cells [20]. 
Finally, one pediatric patient, aged 11 years, was 
recruited into a Phase I/II trial of intravenous 
NVD-HUJ for recurrent glioblastoma, which 
overall demonstrated good tolerability, no major 
side effects and a complete tumor response in one 
other adult patient [21]. 
“Preclinical studies have 
demonstrated the 
potential for oncolytic 
virotherapy as a 
treatment paradigm for 
… childhood tumors…”
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Promising results have been demonstrated in 
adults in terms of safety, tolerability and mul-
tiple-dose delivery data in Phase I and II clini-
cal trials using a range of different viruses for 
treatment of malignant gliomas [6,17]. Recently, 
a handful of oncolytic virus trials for pediatric 
patients with non-CNS solid tumors has been 
developed [22], which will begin to answer ques-
tions regarding dosing, safety and efficacy of 
virotherapy in children. The next step for the 
pediatric field is to amalgamate the knowledge 
gained from preclinical studies together with 
adult and pediatric clinical observations, in 
order to decide which viruses to take forward to 
clinical trials for pediatric CNS tumors. 
There are many questions that must be 
answered before oncolytic virus therapy reaches 
its full potential for pediatric patients with CNS 
disease. First and foremost, safety issues must be 
addressed. One issue that relates solely to pedi-
atric oncology and where minimal information 
is known, is the effect of oncolytic viruses on 
the developing brain and subsequent neuro-
developmental outcomes. Although a murine 
study showed that intracerebral injection of 
modified herpes virus G207 did not adversely 
affect cognitive or behavioral development in 
young mice when compared with saline-treated 
controls, some mice in the treatment group 
developed ventriculomegaly [23]. Although the 
study had limitations and the authors admitted 
concerns that the delivery method of the virus 
itself may have resulted in such findings, it does 
raise the possibility that hydrocephalus may be 
a potential problem for young children receiving 
intracranial virotherapy and that any subsequent 
trials should involve monitoring for this adverse 
effect [23]. Furthermore, tumor location must be 
considered when assessing safety. In particular, 
brainstem tumors, such as DIPG, may be of par-
ticular concern, as local pressure generated from 
immune and inflammatory responses alongside 
viral replication may cause critical, if not fatal 
consequences [24]. One obvious concern for 
pediatricians would be the risk of uncontrollable 
viral replication, resulting in encephalitis and 
subsequent neurodevelopmental sequelae. This 
risk could be overcome by ensuring availability 
of effective antiviral treatments if significant tox-
icity does occur. Effective administration and 
delivery of the virus must also be considered. 
Intratumoral injection limits the number of 
opportunities for treatment in children, whereas 
systemic delivery may be fraught with problems 
in effectively penetrating the blood–brain bar-
rier and overcoming the potential for neutraliza-
tion of the virus by the patient’s immune system 
before it can access its tumor target. Further 
research and clinical experience is required in 
order to optimize virus delivery to pediatric, as 
well as adult, intracranial tumors.
Additional questions relate to the immu-
notherapeutic properties of oncolytic viruses. 
There is clearly a fine balance between mini-
mizing destruction of administered virus by 
the host immune system, while enhancing the 
immune system’s response to kill and ablate 
virus-infected cancer cells [6,25]. One avenue 
of research is currently focused on developing 
cellular carriers that deliver viruses to tumors 
while hiding them from the neutralizing effects 
of the immune system [6]. Furthermore, viruses 
can be modified to express tumor antigens, so 
that when they are appropriately delivered to 
the immune system the anti-tumor immune 
response is enhanced [6]. Specific to pediatrics 
is the fact that young children may not yet have 
been exposed to naturally occurring viruses that 
may subsequently be used for virotherapy, and, 
therefore, will not have built up specific antiviral 
immunity [24]. Whether or not this will enhance 
the efficacy and/or toxicity of systemic oncolytic 
virotherapy in the younger age group remains to 
be determined. Finally, the financial and logis-
tical difficulties in orchestrating clinical trials 
with adequate power in relatively rare childhood 
conditions must be considered, as well as the 
time lag to interpretation of trial results while 
newer and more promising viruses are developed 
in this rapidly evolving field.
Despite recent advances in the field of pedi-
atric neurooncology, morbidity and mortality 
for this patient group remains high and novel 
treatment avenues for unfavorable outcome 
pediatric CNS tumors are desperately required 
[4]. Preclinical studies have demonstrated the 
potential for oncolytic virotherapy as a treat-
ment paradigm for these childhood tumors, 
although very limited, clinical observations in 
children have shown promise. The next step 
for the field is the development and delivery of 
Phase I trials for pediatric CNS tumors evaluat-
ing a range of potential oncolytic viruses. This 
will allow the opportunity to begin to answer 
a range of important clinical questions. Future 
research will concentrate on optimizing virus 
delivery, modulating the role of the child’s 
immune system to prevent viral elimination, 
“…the advent of oncolytic 
virotherapy for pediatric 
CNS tumors opens the 
door to an exciting new 
era for pediatric 
oncology…”
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enhancing anti-tumor immune responses and 
to evaluate the potential for synergistic inter-
actions between oncolytic viruses and existing 
treatment modalities in children. Overall, the 
advent of oncolytic virotherapy for pediatric 
CNS tumors opens the door to an exciting new 
era for pediatric oncology with its potential to 
improve outcomes for the devastating disease 
that is cancer.
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